Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials

Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut–liver axis in liver disease. We reviewed randomized controlled trials on gut...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ting-Rui, Yang, Wen-Juan, Tan, Qing-Hua, Bai, Shuai, Zhong, Huang, Tai, Yang, Tong, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884806/
https://www.ncbi.nlm.nih.gov/pubmed/36726574
http://dx.doi.org/10.3389/fmicb.2022.1004911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884806/
https://www.ncbi.nlm.nih.gov/pubmed/36726574
http://dx.doi.org/10.3389/fmicb.2022.1004911

Ejemplares similares